Nothing Special   »   [go: up one dir, main page]

SI3436019T1 - (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4, 6-triklorofenil)amino)-9h-purin-9-il)-1-metilcikloheksane-1-karboksamid in metode uporabe - Google Patents

(1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4, 6-triklorofenil)amino)-9h-purin-9-il)-1-metilcikloheksane-1-karboksamid in metode uporabe

Info

Publication number
SI3436019T1
SI3436019T1 SI201730930T SI201730930T SI3436019T1 SI 3436019 T1 SI3436019 T1 SI 3436019T1 SI 201730930 T SI201730930 T SI 201730930T SI 201730930 T SI201730930 T SI 201730930T SI 3436019 T1 SI3436019 T1 SI 3436019T1
Authority
SI
Slovenia
Prior art keywords
amino
fluorotetrahydro
purin
trichlorophenyl
methylcyclohexane
Prior art date
Application number
SI201730930T
Other languages
English (en)
Inventor
Zheng Chen
Paul F. Fernandez
Tracy L. Gaebele
Lianfeng Huang
Matthew J. Jackson
Matthew M. Kreilein
Xiaoling Lu
Wenju Wu
Jean Xu
Original Assignee
Signal Pharmaceuticals, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals, Llc filed Critical Signal Pharmaceuticals, Llc
Publication of SI3436019T1 publication Critical patent/SI3436019T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201730930T 2016-04-01 2017-03-31 (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4, 6-triklorofenil)amino)-9h-purin-9-il)-1-metilcikloheksane-1-karboksamid in metode uporabe SI3436019T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317468P 2016-04-01 2016-04-01
EP17776743.1A EP3436019B1 (en) 2016-04-01 2017-03-31 (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahydro-2h-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9h-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use
PCT/US2017/025289 WO2017173218A1 (en) 2016-04-01 2017-03-31 Solid forms of (1s,4s)-4-(2-(((3s4r)-3-fluorotetrahydro-2h-pyran-4-yl) amino)-8-((2,4,6-trichlorophenyl) amino)-9h-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use

Publications (1)

Publication Number Publication Date
SI3436019T1 true SI3436019T1 (sl) 2021-12-31

Family

ID=59960229

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201730930T SI3436019T1 (sl) 2016-04-01 2017-03-31 (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4, 6-triklorofenil)amino)-9h-purin-9-il)-1-metilcikloheksane-1-karboksamid in metode uporabe

Country Status (19)

Country Link
US (2) US10047090B2 (sl)
EP (2) EP3845536A1 (sl)
JP (1) JP6995058B2 (sl)
CN (1) CN109819649B (sl)
AU (1) AU2017240050B2 (sl)
CA (1) CA3019105A1 (sl)
CY (1) CY1124677T1 (sl)
DK (1) DK3436019T3 (sl)
ES (1) ES2895419T3 (sl)
HR (1) HRP20211546T1 (sl)
HU (1) HUE056631T2 (sl)
LT (1) LT3436019T (sl)
MX (1) MX2018011970A (sl)
PL (1) PL3436019T3 (sl)
PT (1) PT3436019T (sl)
RS (1) RS62496B1 (sl)
SI (1) SI3436019T1 (sl)
SM (1) SMT202100604T1 (sl)
WO (1) WO2017173218A1 (sl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2980464T3 (es) 2014-10-06 2024-10-01 Signal Pharm Llc Productos intermedios sintéticos útiles para preparar compuestos de aminopurina sustituidos
CA3018986A1 (en) * 2016-04-01 2017-10-05 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
EP3798224A1 (en) * 2016-06-21 2021-03-31 Teva Pharmaceuticals International GmbH Solid state forms of ixazomib citrate
AU2018345647A1 (en) 2017-10-04 2020-04-16 Celgene Corporation Compositions and methods of use of cis-4-(2-{((3S,4R)-3-fluorooxan-4-yl) amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide
CN111417634A (zh) * 2017-10-04 2020-07-14 细胞基因公司 用于制备顺式-4-[2-{[(3s,4r)-3-氟噁烷-4-基]氨基}-8-(2,4,6-三氯苯胺基)-9h-嘌呤-9-基]-1-甲基环己烷-1-甲酰胺的方法
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US20090215744A1 (en) 2005-11-18 2009-08-27 Astrazeneca Ab Solid Formulations
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
NZ576347A (en) 2006-10-27 2011-10-28 Signal Pharm Llc Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith
ES2400006T3 (es) 2008-04-23 2013-04-04 Farmasierra Manufacturing, S.L. Formulación farmacéutica mejorada a base de ibuprofeno y codeína
WO2011071491A1 (en) 2009-12-09 2011-06-16 Signal Pharmaceuticals, Llc Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US8680076B2 (en) * 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US9466042B2 (en) 2012-01-24 2016-10-11 International Business Machines Corporation Facilitating the design of information technology solutions
US20160082015A1 (en) 2013-04-18 2016-03-24 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
ES2980464T3 (es) 2014-10-06 2024-10-01 Signal Pharm Llc Productos intermedios sintéticos útiles para preparar compuestos de aminopurina sustituidos
CA3018986A1 (en) 2016-04-01 2017-10-05 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
US10047090B2 (en) 2018-08-14
PT3436019T (pt) 2021-11-04
SMT202100604T1 (it) 2021-11-12
HUE056631T2 (hu) 2022-02-28
CN109819649B (zh) 2023-02-28
CY1124677T1 (el) 2022-07-22
LT3436019T (lt) 2021-10-25
EP3436019A1 (en) 2019-02-06
DK3436019T3 (da) 2021-10-11
JP6995058B2 (ja) 2022-02-21
WO2017173218A1 (en) 2017-10-05
AU2017240050A1 (en) 2018-10-11
PL3436019T3 (pl) 2022-01-10
EP3436019A4 (en) 2019-08-28
EP3436019B1 (en) 2021-07-28
JP2019515889A (ja) 2019-06-13
US20170283418A1 (en) 2017-10-05
CN109819649A (zh) 2019-05-28
RS62496B1 (sr) 2021-11-30
US20180362529A1 (en) 2018-12-20
AU2017240050B2 (en) 2021-12-16
CA3019105A1 (en) 2017-10-05
US10513519B2 (en) 2019-12-24
ES2895419T3 (es) 2022-02-21
HRP20211546T1 (hr) 2022-01-07
MX2018011970A (es) 2019-05-20
EP3845536A1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
SMT202100604T1 (it) (1s,4s)-4-(2-(((3s,4r)-3-fluorotetraidro-2h-piran-4-il)ammino)-8-((2,4,6-triclorofenil)ammino)-9h-purin-9-il)-1-metilcicloesano-1-carbossammide e metodi per il loro utilizzo
IL285820A (en) Bicyclic heterocyclyl compounds and their uses
ZA201903932B (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase
EP3518934A4 (en) INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE
EP3509590A4 (en) N-ACYL AMINO ACID COMPOUNDS AND METHOD OF USING
EP3474785A4 (en) SPINE IMPLANT AND METHOD FOR USE THEREOF
EP3558303A4 (en) AMINO ACID COMPOUNDS AND METHOD FOR USE
ZA201805439B (en) Bruton's tyrosine kinase inhibitors
IL281089A (en) LINGO–1 antagonists and uses for the treatment of demyelinating disorders
EP3532528A4 (en) POLYAMIDES DERIVED FROM RENEWABLE SOURCES AND PROCESSES FOR THEIR PREPARATION
ZA201902781B (en) Compositions and methods for the treatment of xerostomia
EP3328380A4 (en) INHIBITOR COMBINATIONS OF BRUTON TYROSINE KINASE AND USES THEREOF
EP3554503A4 (en) INHIBITORS OF PROTEIN 4 (BRD4)
EP3466269A4 (en) COMPOSITION CONTAINING CAFFEINE AND CYCLOALANYLALANINE
EP3466952A4 (en) NOVEL FLIN3 KINASE INHIBITOR AND USE THEREOF
EP3423060A4 (en) IMATINIB FOR USE IN THE TREATMENT OF STROKE
EP3651606A4 (en) PRECIOUS STONE COATINGS AND RELATED MANUFACTURING AND USE PROCEDURES
PT3724196T (pt) Azetidina di-hidrotienopiridinas substituídas e a sua utilização como inibidores de fosfodiesterase
HK1255695A1 (zh) 用於治療眼瞼下垂的組合物和方法
ZA201901505B (en) Phenylalanine-free protein for the treatment of pku
EP3528928A4 (en) FILTER ARTICLES AND METHOD OF MANUFACTURING AND USE THEREOF
GB201720221D0 (en) Automotive components comprising ceramics novel inlays and methods of forming same
EP3607090A4 (en) HIGH PRECISION MICRO CLEANING SYSTEM AND METHOD FOR USE
EP3344239A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE
IL273658A (en) Compounds and methods for using cis-4-[2-{[(3s,4r)-3-fluoroxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]- 1-Methylcyclohexane-1-carboxamide